MetaCap

GeoVax Labs (GOVX) vs Lisata Therapeutics (LSTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GeoVax Labs is the larger company by market cap ($985,459 vs $647,451), about 1.5 times the size. GeoVax Labs converts more of its revenue into profit, with a net margin of -862.3% versus -9756.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOVX+525.43%LSTA-23.17%
+682%+292%-97%
Oct 7, 20261 yearNov 20, 2026
GOVX+544.13%LSTA-15.20%
+574%+250%-73%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOVX versus LSTA key metrics
MetricGOVXLSTA
Share price$1.81$0.8989
Market cap$985.46K$647.45K
1-day change-5.24%-1.22%
YTD return—-51.67%
1-year return—-54.14%
5-year return—-93.89%
EPS (TTM)$-15.03$-28.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.49M$170.00K
Revenue growth (YoY)-37.06%-83.00%
Net income (latest FY)$-21.46M$-16.59M
Operating margin-869.34%-10711.18%
Net margin-862.34%-9756.47%
52-week high$270.60$76.05
52-week low$1.51$0.85
Distance from 52-week high-99.33%-98.82%
Analyst consensusnonenone
Avg. price target upside+452.49%—
Average volume213.41K13.46K
Shares outstanding544.45K720.27K
Employees1921
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GeoVax Labs is more profitable, keeping -862.3 cents of every revenue dollar as net income versus -9756.5 cents for Lisata Therapeutics.
  • GeoVax Labs grew revenue faster in its latest fiscal year (-37.06% vs -83.00%).

About GeoVax Labs

GOVX stock →

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

GOVX vs LSTA FAQ

Which is bigger, GeoVax Labs or Lisata Therapeutics?

GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $647.45K for Lisata Therapeutics (LSTA).

Are GeoVax Labs and Lisata Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons